This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

IntelGenx Technologies 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Dwight Gorham

최고 경영자

US$819.6k

총 보상

CEO 급여 비율	20.2%
CEO 임기	1.3yrs
CEO 소유권	n/a
경영진 평균 재임 기간	2.5yrs
이사회 평균 재임 기간	8.5yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Dwight Gorham 의 보수는 IntelGenx Technologies 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$11m
Dec 31 2023	US$820k	US$165k	-US$10m

보상 대 시장: Dwight 의 총 보상 ($USD 819.56K )은 German 시장( $USD 468.04K ).

보상과 수익: Dwight 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.

CEO

Dwight Gorham (66 yo)

1.3yrs

테뉴어

US$819,564

보상

Mr. Dwight Gorham serves as Chief Executive Officer of IntelGenx Technologies Corp. since April 13, 2023 and also serves as its Director since May 2024 and also Joined the company on April 13, 2023. He ser...

리더십 팀

이름	위치	테뉴어	보상	소유권
Dwight Gorham	CEO & Director	1.3yrs	US$819.56k	데이터 없음
André Godin	President & CFO	9yrs	US$422.32k	0.44% € 117.2k
Tommy Kenny	Senior VP & General Counsel	3.6yrs	US$176.92k	0.13% € 33.6k
Nadine Paiement	Vice-Chair of Scientific Advisory Board and VP of Research & Development - IntelGenx Corp	no data	US$163.33k	0.093% € 24.6k
Karen Kalayajian	Vice President of Finance & Administration	1.3yrs	데이터 없음	0.16% € 42.7k
Stephen Kilmer	Investor Relations Officer	no data	데이터 없음	데이터 없음
Ingrid Zerbe	Corporate Secretary	18.3yrs	데이터 없음	0.053% € 14.1k
Zenoz Pourhassan	VP of Quality Operations of Subsidiary	less than a year	데이터 없음	데이터 없음

2.5yrs

평균 재임 기간

53.5yo

평균 연령

경험이 풍부한 관리: 0IL 의 관리팀은 경험 ( 2.5 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Dwight Gorham	CEO & Director	less than a year	US$819.56k	데이터 없음
Nadine Paiement	Vice-Chair of Scientific Advisory Board and VP of Research & Development - IntelGenx Corp	8.5yrs	US$163.33k	0.093% € 24.6k
Mark Nawacki	Independent Vice Chairman	8yrs	US$83.59k	0% € 0
Horst Zerbe	Chairman & Chairman of Scientific Advisory Board	18.3yrs	US$216.39k	0.0026% € 688.0
Serge Gauthier	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Bernd Melchers	Independent Director	15.3yrs	US$83.59k	0.069% € 18.2k
Barry Greenberg	Member of Scientific Advisory Board	8.5yrs	데이터 없음	데이터 없음
Ludwig Aigner	Member of Scientific Advisory Board	8.5yrs	데이터 없음	데이터 없음
Monika Trzcinska	Independent Director	2.3yrs	US$75.57k	데이터 없음

8.5yrs

평균 재임 기간

61.5yo

평균 연령

경험이 풍부한 이사회: 0IL 의 이사회는 경험(평균 재직 기간 8.5 년)으로 간주됩니다.

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/08/14 12:14
장 마감 주가	2024/05/17 00:00
수익	2024/03/31
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

IntelGenx Technologies Corp. 8 애널리스트 중 0 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Benjamin Haynor	Aegis Capital Corporation
Douglas Loe	Echelon Wealth Partners Inc.
Christian Orquera	First Berlin Equity Research GmbH

This company listing is no longer active

IntelGenx Technologies 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

IntelGenx Technologies Corp. Announces Resignation of Dwight Gorham as Chief Executive Officer

IntelGenx Technologies Corp. Announces Board Resignations

IntelGenx Technologies Corp., Annual General Meeting, May 07, 2024

IntelGenx Technologies Corp. Announces Changes to its Board of Directors

Less than half of directors are independent

IntelGenx Technologies Corp. Announces the Resignation of J. Bernard (Bernie) Boudreau from the Board of Directors

Recent updates

IntelGenx Technologies Corp. Announces Resignation of Dwight Gorham as Chief Executive Officer

IntelGenx Technologies Corp. announced delayed 10-Q filing

ATAI Life Sciences AG entered into an agreement of purchase and sale to acquire the Assets of IntelGenx Technologies Corp. (OTCPK:IGXT).

ATAI Life Sciences AG entered into an agreement of purchase and sale to acquire the Assets of IntelGenx Technologies Corp. (OTCPK:IGXT).

IntelGenx Technologies Corp. Announces Board Resignations

First quarter 2024 earnings released: US$0.023 loss per share (vs US$0.017 loss in 1Q 2023)

Intelgenx Announces First Parkinson’S Disease Patients Dosed with Montelukast Versafilm® in Phase 2 ‘Montpark’ Clinical Trial

IntelGenx Corp. Updates Status of Buprenorphine Buccal Film ANDA

IntelGenx Technologies Corp., Annual General Meeting, May 07, 2024

New major risk - Financial position

Full year 2023 earnings released: US$0.057 loss per share (vs US$0.065 loss in FY 2022)

IntelGenx Technologies Corp. to Report Q4, 2023 Results on Mar 21, 2024

IntelGenx Technologies Corp. Announces Positive Results from Proof-Of-Concept Study to Assess the Palatability, Owner-Perceived Acceptability, and Ease of Repeated Administration of Intelgenx’s VetaFilm® Platform in Healthy Dogs and Cats

IntelGenx Technologies Corp. Announces Changes to its Board of Directors

IntelGenx Corp. Receives Approval to Conduct 'Montpark' Montelukast Versafilm Phase 2 Clinical Trial in Patients with Parkinson's Disease

Third quarter 2023 earnings released: US$0.016 loss per share (vs US$0.015 loss in 3Q 2022)

IntelGenx Technologies Corp. to Report Q3, 2023 Results on Nov 09, 2023

New minor risk - Shareholder dilution

Gensco® Pharma and Intelgenx Announces Rizafilm Commercialization Update in the United States

IntelGenx Corp. Provides Regulatory Update for Xiromed-Partnered Development Candidate, Buprenorphine Buccal Film

IntelGenx Technologies Corp. announced that it expects to receive CAD 9.43492 million in funding from ATAI Life Sciences AG

IntelGenx Technologies Corp. announced that it expects to receive CAD 8.42041 million in funding from ATAI Life Sciences AG

Intelgenx Technologies Corp. Completes Enrollment for `Buena' Montelukast Versafilm® Phase 2A Clinical Trial in Patients with Mild to Moderate Alzheimer's Disease

Second quarter 2023 earnings released: US$0.016 loss per share (vs US$0.017 loss in 2Q 2022)

IntelGenx Technologies Corp. to Report Q2, 2023 Results on Aug 14, 2023

Intelgenx Corp. Completes Enrollment for 'Buena' Montelukast Versafilm®? Phase 2A Clinical Trial in Patients with Mild to Moderate Alzheimer's Disease

Intelgenx Corp. Provides Update on Research Collaboration Evaluating Montelukast Versafilm for the Treatment of Parkinson's Disease

Less than half of directors are independent

IntelGenx Technologies Corp. Announces the Resignation of J. Bernard (Bernie) Boudreau from the Board of Directors

First quarter 2023 earnings released: US$0.017 loss per share (vs US$0.017 loss in 1Q 2022)

IntelGenx Technologies Corp. to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings released: US$0.065 loss per share (vs US$0.068 loss in FY 2021)

IntelGenx Corp. Receives FDA Pdufa Date for Rizafilm®

Third quarter 2022 earnings released: US$0.015 loss per share (vs US$0.013 loss in 3Q 2021)

Third quarter 2022 earnings released: US$0.015 loss per share (vs US$0.013 loss in 3Q 2021)

IntelGenx Technologies Corp. to Report Q3, 2022 Results on Nov 10, 2022

IntelGenx Files Provisional U.S. Patent Application for Advanced Oral Film Formulation Improving Cannabinoid Onset of Action

IntelGenx Receives FDA GDUFA Date for Xiromed-Partnered Development Candidate, Buprenorphine Buccal Film

IntelGenx Corp. Submits Response to CRL from FDA for RIZAPORT VersaFilm

IntelGenx Announces Enrollment Reaches Halfway Mark in ‘BUENA’ Montelukast VersaFilm Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease

Second quarter 2022 earnings released: US$0.017 loss per share (vs US$0.017 loss in 2Q 2021)

IntelGenx Technologies Corp. to Report Q2, 2022 Results on Aug 11, 2022

Less than half of directors are independent

IntelGenx Technologies Corp. Elects Monika Trzcinska As Director

IntelGenx Technologies Corp. to Report Q1, 2022 Results on May 12, 2022

First Patient Dosed in IntelGenx Technologies Corp. Resumed ‘Buena’ Montelukast Versafilm Phase 2A Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease

Third quarter 2021 earnings released: US$0.013 loss per share (vs US$0.015 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.017 loss per share (vs US$0.015 loss in 2Q 2020)

IntelGenx Technologies Corp. announced that it has received $2.1 million in funding

First quarter 2021 earnings released: US$0.02 loss per share (vs US$0.024 loss in 1Q 2020)

Full year 2020 earnings released: US$0.065 loss per share (vs US$0.11 loss in FY 2019)

IntelGenx Technologies Corp. to Report Q4, 2020 Results on Mar 25, 2021

IntelGenx Technologies Corp., Annual General Meeting, May 11, 2021

IntelGenx Receives USPTO Notice of Allowance for its Novel DisinteQTM-Based Disintegrating THC Oral Film

IntelGenx Files Provisional U.S. Patent Application for Novel Vetafilmtm High Loading Oral Film Platform

New 90-day high: €0.30

Intelgenx Receives First Purchase Order for Cbd Filmstrips from Heritage Cannabis

New 90-day high: €0.22

Third quarter 2020 earnings released: US$0.015 loss per share

IntelGenx Corp. Announces Publication of a Study Evaluating Montelukast’s Effect on Neurological Aging

IntelGenx Technologies Corp. to Report Q3, 2020 Results on Nov 12, 2020

Heritage Cannabis Holdings Corp. Signs Letter of Intent with Intelgenx Technologies Corp. for Long-Term Cannabis Filmstrip Supply Agreement

IntelGenx Technologies Corp. announced that it has received $1.2 million in funding

First half earnings released

IntelGenx Technologies Corp. to Report Q2, 2020 Results on Aug 13, 2020

CEO 보상 분석

CEO

테뉴어